Analyst Asthika Goonewardene of Truist Financial maintained a Buy rating on BioNTech SE, retaining the price target of $155.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Asthika Goonewardene has given his Buy rating due to a combination of factors surrounding BioNTech SE’s recent developments in the treatment of Small Cell Lung Cancer (SCLC). The new data presented for BNT327 was promising, demonstrating that the treatment effects observed in China were successfully replicated on a global scale. Moreover, the transition of dosing schedules from Q2W to Q3W aligns better with chemotherapy administration, enhancing the global development efforts.
Additionally, BioNTech SE, in partnership with Bristol-Myers Squibb, is leading the competition in the PD-(L)1 x VEGF bispecifics space for SCLC, with a Phase 3 study currently underway. The potential for a 2028 launch and an estimated $1.4 billion revenue opportunity for BNT327 further supports the Buy rating. The comparable efficacy of the two doses studied, coupled with the lower discontinuation rates of the 20mg/kg Q3W dose, underscores the strategic advantage and potential success of BioNTech’s ongoing efforts.
Goonewardene covers the Healthcare sector, focusing on stocks such as BioNTech SE, Exelixis, and Summit Therapeutics. According to TipRanks, Goonewardene has an average return of -10.2% and a 36.65% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $136.00 price target.